Literature DB >> 31974690

MRI in patients with implanted active devices: how to combine safety and image quality using a limited transmission field?

Laura Lunden1, Stephan Wolff2, Sönke Peters2, Catharina Drews2, Christine Gierloff2, Ulf Jensen-Kondering2, Patrick Langguth2, Jawid Madjidyar2, Tim-Christian Piesch2, Olav Jansen2.   

Abstract

OBJECTIVES: Radio frequency (RF) pulses in magnetic resonance imaging (MRI) can interact with implanted devices and cause tissue damage. However, there are new devices that can safely perform measurements with liberal MRI conditions such as an RF transmission field B1+rms ≤ 2.0 μT. We investigated whether MRI in this case is limited for these technical reasons.
METHODS: We selected typical MRI protocols of six body regions (brain, cervical spine, lumbar spine, knee, liver, heart) using two typical 1.5T MRI scanners. Overall, we adapted 62 sequences to B1+rms conditions and evaluated their diagnostic quality. For this, we measured signal-to-noise-ratio (SNR), contrast-to-noise-ratio (CNR), and geometric deviation (GD) as quality parameters, using phantom studies. For questionnaire studies, we selected pairs of original and adapted sequences in healthy volunteers. Blinded radiologists rated the images as single sequence rating and in direct comparison.
RESULTS: Roughly one-third of the checked sequences were below the B1+rms limit. Here, 56 of the 62 adapted sequences showed at least the same image quality in single ratings. A reduction in SNR and/or CNR was found with 31 sequences and only one sequence with considerably increased GD. Especially, sequences with original high B1+rms values, PD sequences, and sequences of the Siemens knee and heart protocol were difficult to adapt, whereas most TSE and IR sequences had no clinical limitations.
CONCLUSION: By limiting the transmission field to B1+rms ≤ 2.0 μT, clinically relevant MR sequences can be adapted with nearly no reduction in image quality. Despite limiting the transmission field, high-quality MR imaging is possible. We could derive strategies for adaptation. KEY POINTS: • Despite limiting the transmission field, high-quality MRI is possible. • We could derive strategies for adapting the sequences to B1+rms≤ 2.0 μT. • This enables high-quality MRI of different body regions for patients with AD.

Entities:  

Keywords:  Active devices; Magnetic resonance imaging; Patient safety

Mesh:

Year:  2020        PMID: 31974690     DOI: 10.1007/s00330-019-06599-6

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  11 in total

Review 1.  Magnetic resonance safety update 2002: implants and devices.

Authors:  Frank G Shellock
Journal:  J Magn Reson Imaging       Date:  2002-11       Impact factor: 4.813

2.  Clinical safety of brain magnetic resonance imaging with implanted deep brain stimulation hardware: large case series and review of the literature.

Authors:  Ludvic Zrinzo; Fumiaki Yoshida; Marwan I Hariz; John Thornton; Thomas Foltynie; Tarek A Yousry; Patricia Limousin
Journal:  World Neurosurg       Date:  2011 Jul-Aug       Impact factor: 2.104

3.  Magnetic resonance imaging of implanted deep brain stimulators: experience in a large series.

Authors:  Paul S Larson; R Mark Richardson; Philip A Starr; Alastair J Martin
Journal:  Stereotact Funct Neurosurg       Date:  2007-12-12       Impact factor: 1.875

4.  Brain MR imaging at ultra-low radiofrequency power.

Authors:  Subhendra N Sarkar; David C Alsop; Ananth J Madhuranthakam; Reed F Busse; Philip M Robson; Neil M Rofsky; David B Hackney
Journal:  Radiology       Date:  2011-02-25       Impact factor: 11.105

5.  Evaluation of the RF heating of a generic deep brain stimulator exposed in 1.5 T magnetic resonance scanners.

Authors:  Eugenia Cabot; Tom Lloyd; Andreas Christ; Wolfgang Kainz; Mark Douglas; Gregg Stenzel; Steve Wedan; Niels Kuster
Journal:  Bioelectromagnetics       Date:  2012-10-11       Impact factor: 2.010

6.  Three-dimensional brain MRI for DBS patients within ultra-low radiofrequency power limits.

Authors:  Subhendra N Sarkar; Efstathios Papavassiliou; David B Hackney; David C Alsop; Ludy C Shih; Ananth J Madhuranthakam; Reed F Busse; Susan La Ruche; Rafeeque A Bhadelia
Journal:  Mov Disord       Date:  2014-01-17       Impact factor: 10.338

7.  Optimized, Minimal Specific Absorption Rate MRI for High-Resolution Imaging in Patients with Implanted Deep Brain Stimulation Electrodes.

Authors:  A M Franceschi; G C Wiggins; A Y Mogilner; T Shepherd; S Chung; Y W Lui
Journal:  AJNR Am J Neuroradiol       Date:  2016-07-14       Impact factor: 3.825

Review 8.  Recent advances in parallel imaging for MRI.

Authors:  Jesse Hamilton; Dominique Franson; Nicole Seiberlich
Journal:  Prog Nucl Magn Reson Spectrosc       Date:  2017-05-02       Impact factor: 9.795

9.  Low-power inversion recovery MRI preserves brain tissue contrast for patients with Parkinson disease with deep brain stimulators.

Authors:  S N Sarkar; E Papavassiliou; R Rojas; D L Teich; D B Hackney; R A Bhadelia; J Stormann; R L Alterman
Journal:  AJNR Am J Neuroradiol       Date:  2014-03-27       Impact factor: 3.825

10.  Stimulation site within the MRI-defined STN predicts postoperative motor outcome.

Authors:  Fritz Wodarg; Jan Herzog; René Reese; Daniela Falk; Markus O Pinsker; Frank Steigerwald; Olav Jansen; Günther Deuschl; H Maximillian Mehdorn; Jens Volkmann
Journal:  Mov Disord       Date:  2012-04-19       Impact factor: 10.338

View more
  1 in total

1.  Promoting the use of the PI-QUAL score for prostate MRI quality: results from the ESOR Nicholas Gourtsoyiannis teaching fellowship.

Authors:  Francesco Giganti; Alexander P Cole; Fiona M Fennessy; Timothy Clinton; Pedro Lopes Da Frota Moreira; Mariana Costa Bernardes; Carl-Fredrik Westin; Deepa Krishnaswamy; Andriy Fedorov; Daniel A Wollin; Bjoern Langbein; Nicola Frego; Muhieddine Labban; Joy S Badaoui; Steven L Chang; Logan G Briggs; Junichi Tokuda; Alessandro Ambrosi; Alex Kirkham; Mark Emberton; Veeru Kasivisvanathan; Caroline M Moore; Clare Allen; Clare M Tempany
Journal:  Eur Radiol       Date:  2022-06-30       Impact factor: 7.034

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.